Data Entry: Please note that the research database will be replaced by UNIverse by the end of October 2023. Please enter your data into the system https://universe-intern.unibas.ch. Thanks

Login for users with Unibas email account...

Login for registered users without Unibas email account...

 
Cardioprotective medication adherence in Western Australians in the first year after myocardial infarction: restricted cubic spline analysis of adherence-outcome relationships
JournalArticle (Originalarbeit in einer wissenschaftlichen Zeitschrift)
 
ID 4596196
Author(s) Greenland, Melanie; Knuiman, Matthew W.; Hung, Joseph; Nedkoff, Lee; Arnet, Isabelle; Rankin, Jamie M.; Kilkenny, Monique F.; Sanfilippo, Frank M.
Author(s) at UniBasel Arnet, Isabelle
Year 2020
Title Cardioprotective medication adherence in Western Australians in the first year after myocardial infarction: restricted cubic spline analysis of adherence-outcome relationships
Journal Scientific Reports
Volume 10
Number 1
Pages / Article-Number 4315
Keywords medication adherence, Australian PBS, myocardial infarction
Mesh terms Adrenergic beta-Antagonists, therapeutic use; Aftercare, standards; Aged; Angiotensin-Converting Enzyme Inhibitors, therapeutic use; Australia, epidemiology; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors, therapeutic use; Male; Medication Adherence, statistics & numerical data; Models, Statistical; Myocardial Infarction, pathology; Patient Discharge; Prognosis
Abstract Adherence to cardioprotective medications following myocardial infarction (MI) is commonly assessed using a binary threshold of 80%. We investigated the relationship between medication adherence as a continuous measure and outcomes in MI survivors using restricted cubic splines (RCS). We identified all patients aged ≥65 years hospitalised for MI from 2003-2008 who survived one-year post-discharge (n = 5938). Adherence to statins, beta-blockers, renin angiotensin system inhibitors (RASI) and clopidogrel was calculated using proportion of days covered to one-year post-discharge (landmark date). Outcomes were 1-year all-cause death and major adverse cardiac events (MACE) after the landmark date. Adherence-outcome associations were estimated from RCS Cox regression models. RCS analyses indicated decreasing risk for both outcomes above 60% adherence for statins, RASI and clopidogrel, with each 10% increase in adherence associated with a 13.9%, 12.1% and 18.0% decrease respectively in adjusted risk of all-cause death (all p < 0.02). Similar results were observed for MACE (all p < 0.03). Beta-blockers had no effect on outcomes at any level of adherence. In MI survivors, increasing adherence to statins, RASI, and clopidogrel, but not beta blockers, is associated with a decreasing risk of death/MACE with no adherence threshold beyond 60%. Medication adherence should be considered as a continuous measure in outcomes analyses.
Publisher Nature Publishing Group
ISSN/ISBN 2045-2322
edoc-URL https://edoc.unibas.ch/76057/
Full Text on edoc No
Digital Object Identifier DOI 10.1038/s41598-020-60799-5
PubMed ID http://www.ncbi.nlm.nih.gov/pubmed/32152400
ISI-Number WOS:000563341700004
Document type (ISI) Journal Article
 
   

MCSS v5.8 PRO. 0.340 sec, queries - 0.000 sec ©Universität Basel  |  Impressum   |    
19/05/2024